期刊文献+

钙蛋白酶抑制剂ALLN对骨肉瘤细胞增殖和凋亡的影响 被引量:1

Effect of calpain inhibitor ALLN on osteosarcoma cell proliferation and apoptosis
原文传递
导出
摘要 目的 观察钙蛋白酶抑制剂ALLN对骨肉瘤细胞株U2OS、MG63增殖和凋亡的影响.方法 培养骨肉瘤细胞株U2OS和MG63,采用浓度分别为0.1、1.0、10.0、100.0、1 000.0μmol/L的ALLN处理,噻唑蓝(MTT)法检测ALLN对于骨肉瘤细胞株U2OS和MG63体外生长的抑制作用,流式细胞术和Western blot检测ALLN的凋亡诱导作用,克隆形成实验检测ALLN对骨肉瘤细胞株U2OS和MG63克隆形成能力的影响.结果 ALLN对于骨肉瘤细胞株U2OS和MG63有明显的生长抑制作用,U2OS和MG63的半数抑制浓度均约为10 μmol/L,ALLN作用于骨肉瘤细胞株U2OS和MG63后可明显诱导其细胞凋亡,同时ALLN也可降低两种细胞的克隆形成能力.结论 ALLN可明显抑制骨肉瘤细胞株的增殖,促进细胞凋亡. Objective To investigate the effect of calpain inhibitor ALLN on osteosarcoma cell proliferation and apoptosis.Methods Osteosarcoma cell line U2OS and MG63 were treated with 0.1,1.0,10.0,100.0,1000.0 μ mol/L of ALLN,cell proliferation was measured by methyl thiazol tetrazolium(MTT),cell apoptosis was measured by flow cytometry and Western blotting,clone formation assay was performed to study the effect of ALLN on osteosarcoma cell clone formation ability.Results ALLN suppress U2OS and MG63 cell proliferation with an IC50 about 10 μmol/L,ALLN promotes the apoptosis of U2OS and MG63.Morever,ALLN decreases the clone formation ability of U2OS and MG63.Conclusion The calpain inhibitor ALLN suppresses osteosarcoma cell proliferation and promotes apoptosis.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第11期2518-2520,共3页 Chinese Journal of Experimental Surgery
基金 湖北省自然科学基金资助项目(2013CFB240)
关键词 ALLN 骨肉瘤 细胞增殖 细胞凋亡 ALLN Osteosarcoma Cell proliferation Apoptosis
  • 相关文献

参考文献12

二级参考文献42

  • 1陈朝晖,赵军,肖亚军,肖传国.姜黄素诱导人前列腺癌细胞株PC-3凋亡的研究[J].中华实验外科杂志,2005,22(4):507-507. 被引量:9
  • 2Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma : results of a randomized cooperative trial ( COSS- 82) with salvage chemotherapy based on histological tumor response. J Clin Oncol, 1988, 6:329-337.
  • 3Souhami RL, Craft AW, Van der Eijken, et al. Randomised trial of two regimens of chemotherapy in operable osteosareoma : a study of the European Osteosarcoma Intergroup. Lancet, 1997, 350: 911-917.
  • 4Fiocco M, Putter H, van Houwelingen JC. Meta-analysis of pairs of survival curves under heterogeneity: a Poisson correlated gamma-frailty approach. Star Med, 2009, 28:3782-3797.
  • 5Petrilli AS, de Camargo B, Fiho Vo, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol, 2006, 24: 1161- 1168.
  • 6Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults : the first study of the European Osteosarcoma Intergroup. J Clin Oncol, 1992, 10 : 1579-1591.
  • 7Goorin AM, Schwartzentruber D J, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oneology Group Study POG-8651. J Clin Oncol, 2003, 21:1574-1580.
  • 8Jaffe N, Carrasco H, Raymond K, et al. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer, 2002, 95:2202-2210.
  • 9Bacm J G, Longhi A, Cerari M, et al. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients. Cancer, 2006, 106:2701-2706.
  • 10Nathan SS, Gorliek R, Bukata S, et al. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis. Cancer, 2006, 107:1607- 1616.

共引文献9

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部